Subscribe to RSS
DOI: 10.1055/s-0030-1255162
© Georg Thieme Verlag KG Stuttgart · New York
Infektiologie und Tropenmedizin 2010
Infectiology and tropical medicine 2010Publication History
Publication Date:
16 June 2010 (online)
Was ist neu?
-
Aktuelle Epidemiologie: Ausbrüche von Legionellose und Listeriose in Deutschland, Milzbrand bei Heroinkonsumenten, Wildtollwut in Norditalien, Masernepidemie im südlichen Afrika, Polio-Ausbruch in Tadschikistan.
-
Pandemische Influenza H1N1: Frühzeitige Behandlung mit Neuraminidasehemmern senkt Komplikations- und Letalitätsrate bei Risikopatienten, Schutzrate der Impfung zwischen 68 und 97 %, H1N1 2009 in der nächsten saisonalen Grippeimpfung enthalten.
-
HIV: Neue Medikamente für die Erstlinien-Therapie, früherer Therapiebeginn, erste Impfung mit Schutzrate.
-
Antiinfektiva: Micafungin zugelassen für Therapie invasiver und ösophagealer Kandidosen sowie für die Prophylaxe von Candida-Infektionen bei Neutropenie nach Stammzelltransplantation.
-
Tropen- und Reisemedizin: Neue Malariamedikamente in fortgeschrittener klinischer Entwicklung, Impfung gegen Reisediarrhoe in Erprobung, mangelndes Riskobewusstsein der Reisenden für Hepatitis-B- und -C-Infektionen durch Tätowierung und Piercing im Ausland.
-
Impfungen: Neue polyvalente Konjugatimpfstoffe gegen Pneumokokken- und Meningokokken-Infektionen zugelassen, HPV-Impfung schützt mindestens 6 Jahre.
Literatur
- 1 Arbeitsgemeinschaft Influenza des RKI, Wochenbericht 19/2010 (aufgerufen am 7.6.2010). http://influenza.rki.de/Wochenberichte/2009_2010/2010-19.pdf
- 2 Ariano R E, Sitar D S, Zelenitsky S A. et al . Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ. 2010; 182 357-363
- 3 Bätzing-Feigenbaum J, Pruckner U. et al . Spotlight on measles 2010: preliminary report of an ongoing measles outbreak in a subpopulation with low vaccination coverage in Berlin, Germany, January-March 2010. Euro Surveill. 2010; 15 19 527
- 4 Birnkrant D, Cox E. The Emergency Use Authorization of Peramivir for Treatment of 2009 H1N1 Influenza. N Engl J Med. 2009; 361 2204-2007
- 5 Booth M G, Hood J, Brooks T J, Hart A. Health Protection Scotland Anthrax Clinical Network . Anthrax infection in drug users. Lancet. 2010; 375 1345-1346
- 6 Bühler S, Söllner J, Seybold U, Bogner J R. Todesursachen bei HIV-Patienten. MMW Fortschr Med. 2009; 151 56-57
- 7 CDC Homepage (aufgerufen am 7.6.2010) http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm.
- 8 Cooper D A, Heera J, Goodrich J. et al . Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010; 201 803-813
- 9 Cossarini F, Castagna A, Lazzarin A. Raltegravir in treatment naive patients. Eur J Med Res. 2009; 14 Suppl 3 22-29
- 10 Dalton H J, MacLaren G. Extracorporeal membrane oxygenation in pandemic flu: insufficient evidence or worth the effort?. Crit Care Med. 2010; 38 1484-1485
- 11 David M P, Van Herck K, Hardt K. et al . Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol. 2009; 115 (3 Suppl) S1-6
- 12 Dondorp A M, Nosten F, Yi P. et al . Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361 455-467
- 13 ECDC (European Centre for Disease Prevention and Control) Epidemiological Updates, Rabies in Italy, April 8, 2010, http://www.ecdc.europa.eu/en/activities/sciadvice/pages/epidemiological_updates.aspx.
- 14 Eroglu C, Zivalioglu M, Esen S. et al . Detection of Hepatitis B Virus in Used Razor Blades by PCR. Hepatitis Monthly. 2010; 10 22-25
- 15 Frech S A, Dupont H L, Bourgeois A L. et al . Use of a patch containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet. 2008; 371 2019-2025
- 16 French N, Gordon S B, Mwalukomo T. et al . A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010; 362 812-822
- 17 Fretz R, Pichler J, Sagel U. et al . Update: Multinational listeriosis outbreak due to ‘Quargel’, a sour milk curd cheese, caused by two different L. monocytogenes serotype 1/2a strains, 2009 – 2010. Euro Surveill. 2010; 15 pii 19 543
- 18 Granoff D M. Review of meningococcal group B vaccines. Clin Infect Dis. 2010; 50 Suppl 2 S54-65
- 19 Guskey M T, Tsuji B T. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy. 2010; 30 80-94
- 20 Härter G, Zimmermann O, Maier L. et al . Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis. 2010; 50 1249-1251
- 21 Jain S, Kamimoto L, Bramley A M. et al . Hospitalized Patients with 2009 H1N1 Influenza in the United States, April-June 2009. N Engl J Med. 2009; 361 1935-1944
- 22 Krause G, Gilsdorf A, Becker J. et al . Erster Erfahrungsaustausch zur H1N1-Pandemie in Deutschland 2009/2010. Bericht über einen Workshop am 22. und 23. März 2010 in Berlin. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010; 53 510-519
- 23 Lennox J L, Dejesus E, Berger D S. et al . Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. J Acquir Immune Defic Syndr. 2010, April 2010 [Epub ahead of print];
- 24 Löscher T, Bogner J R. Infektiologie und Tropenmedizin 2009: Was ist neu?. Dtsch Med Wochenschr. 2009; 134 1343-1348
- 25 Mills A M, Nelson M, Jayaweera D. et al . Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009; 23 1679-1688
- 26 Novak R, Shlaes D M. The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs. 2010; 11 182-191
- 27 Nowroozalizadeh S, Mansson F, SZ. et al . Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Infect Dis. 2010; 201 1150-1154
- 28 Ortiz R, Dejesus E, Khanlou H. et al . Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008; 22 1389-1397
- 29 Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. National Institutes of Health 1 – 12 – 2009. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
- 30 Petrignani M, Harms M, Verhoef L. Update: a food-borne outbreak of hepatitis A in the Netherlands related to semi-dried tomatoes in oil, January-February 2010. Euro Surveill. 2010; 15 pii 19 572
- 31 Pfeffer M, Hanus I, Löscher T. et al . Chikungunya fever in two German tourists returning from the Maldives, September, 2009. Euro Surveill. 2010; 15 (13) pii) 19 531
- 32 Reisler R B, Han C, Burman W J. et al . Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr. 2003; 34 379-386
- 33 Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S. et al, MOPH-TAVEG Investigators . Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361 2209-2220
- 34 Rianthavorn P, Prianantathavorn K, Wuttirattanakowit N. et al . An outbreak of chikungunya in southern Thailand from 2008 to 2009 caused by African strains with A226V mutation. Int J Infect Dis. 2010, Apr 21. [Epub ahead of print];
- 35 Robert Koch-Institut . Zum Verlauf der HIV-Epidemie in Deutschland bis Ende 2009. RKI Epidem Bull. 2009; Nr. 48 491-502
- 36 Robert Koch-Institut . Telefonische Erhebung zur Impfung gegen die pandemische Influenza (H1N1) 2009. Ergebnisse aus den Befragungen bis Februar 2010. RKI Epidem Bull. 2010; Nr. 13 114-115
- 37 Robert Koch-Institut . Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Virushepatitis B, C und D im Jahr 2009. RKI Epidem Bull. 2010; Nr. 20 177-187
- 38 Robert Koch-Institut . Rückblick: Epidemiologie und Infektionsschutz im zeitlichen Verlauf der Influenzapandemie (H1N1) 2009. RKI Epidem Bull. 2010; Nr. 21 191-197
- 39 Robert Koch-Institut . Klinische Wirksamkeit der Impfung gegen pandemische Influenza (H1N1) 2009 in Deutschland. RKI Epidem Bull. 2010; Nr. 21 198-201
- 40 Romanowski B, de Borba P C, Naud P S. et al, GlaxoSmithKline Vaccine HPV-007 Study Group . Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009; 374 1975-1985
- 41 Saleem M, Nazir M, Ali M S. et al . Antimicrobial natural products: an update on future antibiotic drug candidates. Nat Prod Rep. 2010; 27 238-254
- 42 Taylor W R, Thinh B N, Anh G T. et al . Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One. 2008; 3 e3410
- 43 The Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators . Extracorporeal Membrane Oxygenation for 2009 Influenza A (H1N1) Acute Respiratory Distress Syndrome. JAMA. 2009; 302 1888-1895
- 44 Tshefu A K, Gaye O, Kayentao K. et al, Pyronaridine-artesunate Study Team . Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010; 375 1457-1467
- 45 van Burik J A, Ratanatharathorn V, Stepan D E. et al, National Institute of Allergy and Infectious Diseases Mycoses Study Group . Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004; 39 (10) 1407-1416
- 46 Vandekerckhove L, Verhofstede C, Vogelaers D. Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. J Antimicrob Chemother. 2009; 63 1087-1096
- 47 van der Hoek W, Dijkstra F, Schimmer B. et al . Q fever in the Netherlands: an update on the epidemiology and control measures. Euro Surveill. 2010; 15 19 520
- 48 Vollbrecht T, Brackmann H, Henrich N. et al . Impact of changes in antigen level on CD38/PD-1 co-expression on HIV-specific CD8 T cells in chronic, untreated HIV-1 infection. J Med Virol. 2010; 82 358-370
- 49 von Baum H, Härter G, Essig A. et al . Preliminary report: outbreak of Legionnaires disease in the cities of Ulm and Neu-Ulm in Germany, December 2009 – January 2010. Euro Surveill. 2010; 15 19 472
- 50 WHO Global Polio Eradication Initiative (zuletzt aufgerufen am 7.6.2010). http://www.polioeradication.org/casecount.asp
- 51 WHO Pandemic (H1N1) 2009 – update 102 (zuletzt aufgerufen am 7.6.2010). http://www.who.int/csr/don/2010_05_28/en/index.html
- 52 Wichmann O, Stocker P, Poggensee G. et al . Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009 – 2010. Euro Surveill. 2010; 15 (18) pii) 19561
- 53 The Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group . Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS 2010 May 6. [Epub ahead of print].
- 54 Bassat W, Mulenga M, Tinto H. et al . Dihydroartemisinin- piperaquine and artemether- lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. Plos One. 2009; 4 e7871
Prof. Dr. med. Thomas Löscher
Abteilung für Infektions- und Tropenmedizin, Klinikum
der Ludwig-Maximilians-Universität München
Leopoldstraße
5
80802 München
Phone: 089/21803517
Email: loescher@lrz.uni-muenchen.de